Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma

Sponsor
Takeda
Study ID
NCT05100082
Status
Completed

Conditions

  • Hepatocellular Cancer

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a survey in Japan of Cabozantinib tablets used to treat Japanese people with a type of liver cancer called hepatocellular carcinoma. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects from Cabozantinib. During the study, participants with hepatocellular carcinoma will take Cabozantinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Cabozantinib for 12 months.

Key Dates

Start date
Nov 17, 2021
Status verified
Dec 2025
Primary completion
Nov 30, 2025
Completion
Nov 30, 2025

Study Design

Enrollment
263 participants (actual)

Arms

  • Arm: Cabozantinib 60 mg
    Cabozantinib 60 milligrams (mg) tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.

Primary Outcome Measure

Number of Participants with Adverse Events Related to Hepatic Failure, Hepatic Dysfunction, and Pancreatitis [ Time Frame: Up to 12 months ]

Related Studies